Aptabio Therapeutics압타바이오
293780 · KOSDAQ · ₩293780 · 압타바이오
₩5,090▼ ₩220 (4.14%)End-of-day · Oct 30, 2026 · End-of-day prices.
Filings
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (조영제유발급성신장손상(CIAKI) 치료제 Isuzinaxib(APX115)의 임상시험 제2상 Topline data수령)Oct 14, 2026Open on DART
Predicted impact: Medium· Actual: −7.4% vs sector, volume 1.1× normal (5 trading days)
Phase 2 topline data for a drug candidate; market reaction depends on results, which are not given.
- Investor relations (IR) event기업설명회(IR)개최Sep 2, 2026Open on DART
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) After Issuance and Before Maturity전환사채(해외전환사채포함)발행후만기전사채취득Aug 24, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Adjustment of Conversion Price전환가액의조정Jul 24, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (ABF101의 경구투여 시 안전성, 내약성 및 약동학을 평가하기 위한 단회 및 반복 투여, 단계적 용량증량, 제1상 임상시험에 대한 미국 FDA Remove Clinical Hold 공문 수령)Jun 16, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (조영제유발급성신장손상(CIAKI)치료제 Isuzinaxib(APX115)의 미국 FDA 2상 임상시험계획(IND)변경승인)Apr 14, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Apr 6, 2026Open on DART
- Change of Head Office Location본점소재지변경Apr 1, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 31, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Mar 27, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Mar 26, 2026Open on DART
- Audit report submitted감사보고서제출Mar 23, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 23, 2026Open on DART
- Amended: Shareholders' meeting called[기재정정]주주총회소집결의Mar 16, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 16, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (조영제유발급성신장손상(CIAKI) 치료제 Isuzinaxib(APX115)의 국내 2상 임상시험계획(IND) 변경승인)Mar 13, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인신청) (조영제유발급성신장손상(CIAKI)치료제 Isuzinaxib(APX115)의 미국 FDA 2상 임상시험계획(IND)변경승인신청)Mar 13, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (ABF101의 경구투여 시 안전성, 내약성 및 약동학을 평가하기 위한 단회 및 반복 투여, 단계적 용량증량, 제1상 임상시험에 대한 미국 FDA Clinical Hold 공문 수령)Feb 23, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Feb 9, 2026Open on DART
- Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 9, 2026Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Feb 9, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획변경승인신청) (조영제유발급성신장손상(CIAKI) 치료제 Isuzinaxib(APX115)의 국내 2상 임상시험계획(IND) 변경승인신청)Feb 6, 2026Open on DART
- Adjustment of Conversion Price전환가액의조정Dec 24, 2025Open on DART
- Exercise of Conversion Rights전환청구권행사Dec 23, 2025Open on DART
- Exercise of Conversion Rights전환청구권행사Dec 22, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2025Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (ABF101의 미국 FDA 제1상 임상시험계획(IND)승인)Oct 23, 2025Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (ABF101의 미국 FDA 제1상 임상시험계획 승인신청(IND))Aug 28, 2025Open on DART
- Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (ABF101의 미국 FDA 제1상 임상시험계획 승인신청(IND))Jul 28, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Jul 10, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Jul 7, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (APX343A의 제1상 임상시험계획(IND) 승인)Jun 18, 2025Open on DART
- Other management matters기타경영사항(자율공시) ([국책과제 선정] 국가신약개발사업단(KDDF)(당뇨병성 신증 환자에서 panNOX 저해제 아이수지낙시브 임상 2b상 연구 ))Jun 18, 2025Open on DART
- Merger Completion Report (Merger)합병등종료보고서(합병)Jun 4, 2025Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)May 28, 2025Open on DART
- Adjustment of Conversion Price전환가액의조정May 26, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최May 19, 2025Open on DART
- Quarterly report (Mar 2025)분기보고서 (2025.03)May 15, 2025Open on DART
- Major Matters Report (Exercise of Convertible Bond Call Option by Third Party)주요사항보고서(제3자의전환사채매수선택권행사)May 12, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Apr 2, 2025Open on DART
- Amended attachment: Merger decision[첨부정정]주요사항보고서(회사합병결정)Apr 2, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Apr 1, 2025Open on DART
- Merger decision주요사항보고서(회사합병결정)Apr 1, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Mar 27, 2025Open on DART
- Annual general meeting results정기주주총회결과Mar 26, 2025Open on DART
- Audit report submitted감사보고서제출Mar 18, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: Aptabio Therapeutics / 압타바이오 / 293780 / KRX:293780
Source: KRX statistical information